Abstract: In recent years， the researches on chimeric antigen receptor（CAR） engineered T lymphocytes in curing cancer have made great progresses. CAR has several technical advantages， such as endowing great targeting ability to CAR-engineered T cells， breaking the state of immune tolerance and so on， which make great progress in curing Hematology. Because of existed off-target effects of solid tumor and the poor penetration of immune cells into the tumor tissue， this application is still in phase I clinical trial. This paper will make a review of the application of CAR enjineered T lymphocyte to some solid tumor experiments.